Researchers from the University of Wisconsin Departments of Pediatrics, Human Oncology, Medical Physics, Medicine, and Radiology (including UW Overall Multiple PIs, Drs. Jamey Weichert, Radiology, and Zachary Morris, Human Oncology) were recently awarded a Program Project Grant from the National Institutes of Health-National Cancer Institute (NIH-NCI) entitled, “Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response.” The overall P01, funded for five years in the amount of ~$2.5 million in total costs annually, includes an administrative core, three scientific cores, and four scientific projects, all focused on the development of a fundamental understanding of the complex interplay between two rapidly emerging fields in cancer therapy: 1) targeted radionuclide therapy (TRT) and 2) immunotherapy. Paul Sondel, MD, PhD (Professor, Division of Hematology, Oncology & Bone Marrow Transplant), will lead Project 3, entitled, “Combining Targeted Radionuclide Therapy with a Localized In Situ Vaccine to Overcome Immune Suppression in the Tumor Microenvironment and Augment T Cell Response.” The goals of Project 3 are to utilize immunocompetent mouse models of cold neuroblastoma and sarcomas, with the in vivo goal to use TRT to help eradicate all cancer in mice bearing macroscopic tumors in two separate sites as well as disseminated micro-metastases. Project 3 provides support for the Sondel Lab team in the amount of $326,693 of total costs annually.